Blood Pressure Monitoring in Chronic Kidney Disease
|
|
- Johnathan Howard
- 6 years ago
- Views:
Transcription
1 Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT
2 American Society of Hypertension, Inc. (ASH) Disclosure of Relationships Over the past 12 months Aldo J. Peixoto, MD Grant/Research Support: Veterans Administration HSR&D Honoraria: American Society of Nephrology, Society of Critical Care Medicine, Novartis Other Support: International Society of Nephrology (Sister Renal Centers Program)
3 Educational Objectives 1. To review the profile of out-of-office BP in patients with CKD 2. To review the prognostic role of out-of-office BP in patients with CKD 3. To discuss possible treatment implications of the patterns of out-of-office BP to patients with CKD
4 Premises of this talk 1. ABPM (and HBP) bear closer relationships with of target organ damage in HTN than clinic BP. 2. ABPM (and HBP) are better predictors of hard outcomes in HTN than clinic BP. 3. Night-time BP is marginally better than daytime BP to predict hard outcomes in HTN. 4. ABPM (and home BP) are cost-saving in the diagnosis of HTN compared with clinic BP.
5 CKD-specific issues related to BP measurement
6 CKD-specific issues related to BP measurement Presence of AVF in CKD 4 patients
7 CKD-specific issues related to BP measurement Presence of AVF in CKD 4 patients Visit-to-visit variability of office BP is increased in CKD
8 Visit-to-visit variability (standard deviation) of SBP by egfr in NHANES III egfr, ml/min/1.73 m to 59 <45 P-trend Unadjusted SD 7.5 (5.3) 9.1 (5.4) 12.2 (7.4) <0.001 Model 1 0 (ref) 0.47 (0.78) 2.76 (1.28) <0.001 Model 2 0 (ref) 0.25 (0.74) 1.49 (1.21) Model 1 adjusted for age, race-ethnicity, and sex, mean SBP Model 2 adjusted for age, race-ethnicity, and sex, mean SBP across visits Courtesy: Paul Muntner, PhD
9 CKD-specific issues related to BP measurement Presence of AVF in CKD 4 patients Visit-to-visit variability of office BP is increased in CKD Masked and white coat effects are common in CKD
10 Prevalence of masked HTN, white coat HTN, and masked and WC effects in CKD N=980 in 6 studies Masked HTN = 8% [95%CI = ] White coat HTN = 18% [95% CI = ] M and WC effects (impact on control assessment) 40% controlled in the office, not at home 31% controlled at home, not in the office Bangash and Agarwal. CJASN 2009; 4:
11 Ambulatory BP is often uncontrolled in African-American patients with CKD and controlled office BP Pogue et al. Hypertension 2009; 53: 20-7
12 CKD-specific issues related to BP measurement Presence of AVF in CKD 4 patients Visit-to-visit variability of office BP is increased in CKD Masked and white coat effects are common in CKD Nocturnal HTN and non-dipping are the norm in CKD
13 Nocturnal hypertension is common in CKD and worsens with lower levels of renal function N = Farmer et al. Nephrol Dial Transplant 1997; 12:
14 Prevalence and profile of different dipping status in AASK All Subjects N=617 Dippers N=122 (20%) Non-Dippers N=253 (41%) Reverse Dippers N=242 (39%) Office BP 134/80 133/79 136/81 132/79 24h BP 137/81 131/78 137/82 139/82 Daytime BP 138/83 136/82 138/83 137/82 Night-time BP 134/77 116/67 132/76 146/84 Age = 60±10 years GFR = 44±16 ml/min Pogue et al. Hypertension 2009; 53: 20-7
15 Potential mechanisms responsible for nondipping in CKD Autonomic neuropathy Sympathetic overactivity Overactivity of the RAAS Sleep disordered breathing Decreased activity of vasodilatory and natriuretic systems, impaired natriuresis Decreased physical activity Interactions of renal function and proteinuria Peixoto and White. Kidney Int 2007; 71: 855 Agarwal, Peixoto, Santos and Zoccali. Blood Press Monit 2009; 14: 2-11
16 Interactions between proteinuria, low GFR and circadian BP + CKD, + PROT No CKD, + PROT N = 336 elderly veterans 55% with CKD 34% DM2 36% GN 45% no CKD + CKD, no PROT No CKD, no PROT Agarwal et al. Nephrol Dial Transplant. 2009; 24:
17 Take Home Points (#1) Masked HTN effect is common in CKD out-of-office BP is a must for the evaluation of the patient. Nocturnal hypertension is a hallmark of the BP profile in advanced CKD ABPM may have special relevance.
18 Prognostic Implications of Different BP Measurements in CKD
19 ABPM improves the definition of hypertension-associated outcomes in CKD N = 217 males 42% DM, 92% on HTN Rx GFR 45 ml/min F/U 3.5 years 52 deaths, 36 ESRD Agarwal and Andersen. Kidney Int 2006; 69:
20 ABPM improves the definition of hypertension-associated outcomes in CKD HR for ESRD after adjustment for clinic BP = 2.2 [ ] Agarwal and Andersen. Kidney Int 2006; 69:
21 ABPM is an independent marker of risk of CV and renal events in CKD N = 436, GFR 43 ml/min, 37% DM F/U = 4.2 years Adjusted for age, sex, bmi, diabetes mellitus, CV disease, hemoglobin level, proteinuria, and GFR, and stratified for center Minutolo et al. Arch Intern Med 2011; 171:
22 Relationship between ambulatory BP and outcomes in CKD CV Events ESRD Minutolo et al. Arch Intern Med 2011; 171:
23 Hazard Ratios (HR) Relating Baseline BP Variables to Subsequent Renal Outcomes HR 95% CI P-value 24-hour SBP 1.24 ( ) <0.001 Nighttime SBP 1.17 ( ) <0.001 Daytime SBP 1.27 ( ) <0.001 Clinic SBP 1.28 ( ) <0.001 N = 617, baseline GFR 43.5 ml/min Renal endpoint = Doubling of serum Creat, ESRD or Death Results are adjusted by age, gender, baseline egfr, BMI and number of comorbid conditions, and are stratified by randomization group. Courtesy: Francis Gabbai, MD ASN 2009: manuscript under review
24 Hazard Ratios (HR) Relating Baseline BP Variables to Subsequent Cardiovascular Outcomes HR 95% CI P-value 24-hour SBP 1.31 ( ) <0.001 Nighttime SBP 1.23 ( ) <0.001 Daytime SBP 1.32 ( ) <0.001 Clinic SBP 1.23 ( ) <0.001 N = 617, baseline GFR 43.5 ml/min CV Endpoint: Hospitalized MI, CHF, stroke, revascularization or CV death Results are adjusted by age, gender and are stratified by randomization group. Courtesy: Francis Gabbai, MD ASN 2009: manuscript under review
25 =clinic SBP less than 130 mmhg; uncontrolled=clinic SBP more than 130 mmhg. NT SBP: night time SBP DT SBP: day time SBP Additive predictability for Renal outcomes of ABPM SBPs in models including clinic SBP Overall Controlled clinic SBP < 130 mmhg Uncontrolled clinic SBP > 130 mmhg Event (Rate) 200 (0.079) 65 (0.055) 135 (0.099) HR P-value HR P value HR P value 24-HR SBP Nighttime SBP Daytime SBP Courtesy: Francis Gabbai, MD ASN 2009: manuscript under review
26 Additive predictability for cardiovascular outcomes of ABPM SBPs in models including clinic SBP Overall Controlled clinic SBP < 130 mmhg Uncontrolled clinic SBP > 130 mmhg Event (Rate) 99 (0.040) 38 (0.033) 61 (0.045) HR P-value HR P value HR P value 24-HR SBP Nighttime SBP Daytime SBP Courtesy: Francis Gabbai, MD ASN 2009: manuscript under review
27 Home vs. Clinic BP and risk of renal endpoints in CKD Risk per SD of Home Systolic BP N = 217 * adjusted for age, race, diabetes mellitus, log protein/creatinine ratio, estimated Modification of Diet in Renal Disease glomerular filtration rate, serum albumin, hemoglobin, and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use. Agarwal. Kidney Int 2006; 69:
28 Home vs. ABPM vs. Clinic and cardiovascular risk in CKD N=217 Cardiovascular outcomes were defined as a composite outcome of myocardial infarction, stroke or death. Agarwal and Andersen. Am J Nephrol 2006; 26:
29 Nocturnal HTN and baseline target organ damage in the AASK Cohort Study Lowest Middle Highest Nsbp <126 Nsbp Nsbp >141 P N=215 N=202 N=200 Echo LVH 57% 70% 81% < Prot/Cr ratio 0.17± ± ±1.05 < Prot/Cr > % 30% 43% < Non-dippers = 41% Reverse dippers = 39% Pogue et al. Hypertension 2009; 53: 20-7
30 Nocturnal hypertension is associated with worse outcomes in CKD -1.3% Unadjusted P< % N = 322 patients referred for ABPM 137 dippers, 185 non-dippers Median follow-up = 3.2 years Davidson et al. Arch Intern Med 2006;166:846-52
31 Nocturnal hypertension and ESRD risk in older men with CKD N = 217 Follow-up = 3.5 years 52 deaths, 36 ESRD Agarwal and Andersen. Kidney Int 2006; 69:
32 Lack of independent effect of circadian BP rhythm on mortality or ESRD NON-DIPPERS v. DIPPERS HR 95% CI P All-cause mortality Unadjusted Adjusted for 24h SBP Adjusted for age, 24h SBP End-stage renal disease Unadjusted Adjusted for 24h SBP Adjusted for age, 24h SBP N = 322 (179 with CKD), Follow-up for up to 8.7 years 116 deaths (60.4/1,000 pt-years, full cohort), 57 ESRD (69.2/1,000 pt-years, CKD cohort) Agarwal et al. Am J Nephrol 2009; 30:
33 Dipping status and outcomes in 4 Italian cohorts Adjusted for age, sex, body mass index, diabetes mellitus, CV disease, hemoglobin level, proteinuria, glomerular filtration rate, and 24-h mean BP. Minutolo et al. Arch Intern Med 2011; 171:
34 Take Home Points (#2) ABPM is stronger predictor than clinic BP of renal and CV events and death in CKD patients. ABPM is better than home BP to predict CV risk in CKD. Home BP is better than clinic BP to predict renal endpoints in CKD. The independent prognostic role of dipping status and nocturnal HTN in CKD remains uncertain.
35 Therapeutic Implications of BP monitoring in CKD
36 Treatment Opportunities ABPM and home have been used to guide the treatment of essential HTN.
37 Treatment Opportunities ABPM and home have been used to guide the treatment of essential HTN. ABPM targets were successfully used in the ESCAPE trial. Wuhl et al. N Engl J Med 2009; 361: 1369
38 Treatment Opportunities ABPM and home have been used to guide the treatment of essential HTN. ABPM targets were successfully used in the ESCAPE trial. Home telemedicine is effective in clinical trials in essential HTN.
39 Telemonitoring and self-management result in better BP control in patients with uncontrolled HTN BP Decline 6 months 12 months Intervention (N=234) 12.9/ /7.5 Control (N=246) 9.2/ /4.8 Difference 3.7/ /2.7 Median = 152 readings/year 74% obtained >90% of expected readings 8% did not complete basic training 12% ceased monitoring during the study McManus et al. Lancet 2010; 376:
40 Web communication under pharmacist supervision improves BP control N = 730 at 12 months Usual Care HBP/Web HBP/Web/Ph armd Adjusted delta SBP Adjusted delta DBP % reaching target 31% 36% 56% Anti-HTN drugs (baseline 1.6) Adjusted RR Ref All comparisons significant for UC vs. HW and H/W vs. HW/PharmD Green et al. JAMA 2008; 299:
41 Blood pressure (mmhg) Effectiveness of home telemedicine for HTN N=107 HT, 107 controls HBPT Control 137±18 134±17 132±17 133±15 132±16 133±18 132±15 133±14 74±12 73±11 71±12 73±11 70±12 72±13 71±12 72±11 Δ SBP Diff 3.6 [-2.0, 9.2] P=0.21 Δ DBP Diff 0.5 [-3.5, 4.5] P=0.81 Uncontrolled HT 33%, C 38% P= [-2.4, 8.0] P= [-2.3, 3.7] P=0.64 HT 31%, C 37% P= [-2.3, 4.8] P= [-2.6, 3.1] P=0.88 HT 30%, C 31% P=0.51 Baseline 3 months 6 months 12 months
42 Treatment Opportunities ABPM and home have been used to guide the treatment of essential HTN. ABPM targets were successfully used in the ESCAPE trial. Home telemedicine is effective in clinical trials in essential HTN. No data in CKD. Chronopharmacologic approaches may improve outcomes in essential HTN and in CKD.
43 Bedtime administration of valsartan is associated with decreased albuminuria in HTN night/day ratio vs. proteinuria (R=0.22, P=0.03) AM valsartan = 102 PM valsartan = 98 3-month study Hermida et al. Hypertension 2005; 46: 960-8
44 Non-dipping can be reverted pharmacologically in CKD with potentially beneficial effects Drug shift to PM improves dipping Drug shift to PM lowers proteinuria N = 32 Age = years egfr = ml/min PER = mg/day Minutolo et al. Am J Kidney Dis 2007; 50:
45 Cardiovascular outcomes with bedtime antihypertensive administration in patients with early CKD N=661, PROBE design, single center GFR 65 ml/min, 33% DM, 7% previous CVD 66% non-dippers at baseline Either all drugs on awakening or 1 or more at bedtime Bedtime agents: ACEi: ramipril or spirapril ARB: valsartan, telmisartan, olmesartan CCB: amlodipine or nifedipine GITS End-of-study BP: lower at night 123/63 vs 117/65 (P<0.001) End-of-study non-dippers: 41% vs 71% (P<0.001) Hermida et al. JASN 2011; 22:
46 Cardiovascular outcomes with bedtime antihypertensive administration in patients with early CKD N=661, PROBE design, single center F/U 5.4 years, 139 events Hazard Ratios 0.31 [0.21 to 0.46] 0.28 [0.13 to 0.61] Hermida et al. JASN 2011; 22:
47 Differential relationship between achieved clinic and sleep BP and outcomes in MAPEC Quintiles of achieved SBP Hermida et al. JASN 2011; 22:
48 CV events/1,000 person-years Potential risks: increased risk of stroke in extreme dippers with mild CKD N=811, F/U=41 months Adjusted* Hazard Ratios: ED = 2.59 [ ] ND = 1.83 [ ] ED = 165 (21%), D = 343 (42%), ND = 303 (37%) *Adjusted for age, sex, BMI, smoking, DM, hyperlipidemia, antihypertensive treatment, egfr, 24h SBP Ishikawa et al. J Clin Hypertens 2008; 10:
49 Potential effects of manipulation of nocturnal BP in CKD How much is too much? Minutolo et al. Arch Intern Med 2011; 171:
50 Take Home Points (#3) Treatment strategies that incorporate outof-office BP are feasible in CKD. Their efficacy and safety remain to be confirmed, especially as it pertains to bedtime medication dosing.
51 American Society of Hypertension, Inc. (ASH) Disclosure of Relationships Over the past 12 months Aldo J. Peixoto, MD Grant/Research Support: Veterans Administration HSR&D Honoraria: American Society of Nephrology, Society of Critical Care Medicine, Novartis Other Support: International Society of Nephrology (Sister Renal Centers Program)
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK. Michael Smolensky, Ph.D. The University of Texas Austin & Houston
AGING, BLOOD PRESSURE & CARDIOVASCULAR DISEASE EVENT RISK Michael Smolensky, Ph.D. The University of Texas Austin & Houston Disclosures Partner: Circadian Ambulatory Diagnostics Consultant: Spot On Sciences
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationHypertension: What s new since JNC 7. Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF
Hypertension: What s new since JNC 7 Harold M. Szerlip, MD, FACP, FCCP, FASN, FNKF Disclosures Spectral Diagnostics Site investigator Eli Lilly Site investigator ACP IM ITE writing committee NBME Step
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationImportance of Ambulatory Blood Pressure Monitoring in Adolescents
Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationSeung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine
Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More information신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure
신장환자의혈압조절 K/DOQI Clinical practice guidelines on Hypertension and Antihypertensive agents in CKD 나기영 Factors involved in the regulation of blood pressure Renal function curve MAP (mmhg) Central role of
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationAmbulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD
Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease Rajiv Agarwal, MD Summary: Hypertension is an important risk factor for adverse cardiovascular and renal outcomes, particularly
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationDiabetes and kidney disease.
Diabetes and kidney disease. What are the implications? Can it be prevented? Nice 18 june 2010 Lars G Weiss. M.D. Ph.D. Department of Neprology Central Hospital Karlstad Sweden Diabetic nephropathy vs
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationTodd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM
Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationCKD and risk management : NICE guideline
CKD and risk management : NICE guideline 2008-2014 Shahed Ahmed Consultant Nephrologist shahed.ahmed@rlbuht.nhs.uk Key points : Changing parameters of CKD and NICE guidance CKD and age related change of
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationAggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
http://www.kidney-international.org & 2013 International Society of Nephrology Aggressive blood pressure reduction and renin angiotensin system blockade in chronic kidney disease: time for re-evaluation?
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationDiabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin
Diabetic Kidney Disease Tripti Singh MD Department of Nephrology University of Wisconsin Disclosures I have no financial relationship with the manufacturers of any commercial product discussed during this
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More informationAbnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and normalization by bedtime hypertension chronotherapy
Nephrol Dial Transplant (2014) 29: 1160 1167 doi: 10.1093/ndt/gft285 Advance Access publication 5 September 2013 Abnormalities in chronic kidney disease of ambulatory blood pressure 24 h patterning and
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationOutline. Outline 10/14/2014 CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationAGING KIDNEY IN HIV DISEASE
AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationCARDIO-RENAL SYNDROME
CARDIO-RENAL SYNDROME Luis M Ruilope Athens, October 216 DISCLOSURES: ADVISOR/SPEAKER for Astra-Zeneca, Bayer, BMS, Daiichi-Sankyo, Esteve, GSK Janssen, Lacer, Medtronic, MSD, Novartis, Pfizer, Relypsa,
More informationChronic Pediatric Hypertension
Chronic Pediatric Hypertension Nephrology Grand Round 3/13/2015 Mahmoud Kallash M.D Outline Definition of hypertension (HTN) Challenges in diagnosing HTN Epidemiology Causes and evaluation of HTN Management
More informationOutline. Outline CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW 7/23/2013. Question 1: Which of these patients has CKD?
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationKDIGO Controversies Conference on Blood Pressure in CKD
KDIGO Controversies Conference on Blood Pressure in CKD September 7-10, 2017 Edinburgh, Scotland Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationLaunch Meeting 3 rd April 2014, Lucas House, Birmingham
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Launch Meeting 3 rd April 2014, Lucas House, Birmingham Prof Sunil Bhandari
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationEffective Health Care Program
Comparative Effectiveness Review Number 37 Effective Health Care Program Chronic Kidney Disease Stages 1 3: Screening, Monitoring, and Treatment Executive Summary Objectives This systematic review evaluates
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationNew Antihypertensive Strategies to Improve Blood Pressure Control
New Antihypertensive Strategies to Improve Blood Pressure Control Antonio Coca, MD, PhD,, FRCP, FESC Hypertension and Vascular Risk Unit Department of Internal Medicine. Hospital Clínic (IDIBAPS) University
More informationDiabetes and Hypertension
Diabetes and Hypertension William C. Cushman, MD, FAHA, FACP, FASH Chief, Preventive Medicine, Veterans Affairs Medical Center Professor, Preventive Medicine, Medicine, and Physiology University of Tennessee
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationUpdate on HTN and ABPM. Raj Padwal Division of General Internal Medicine University of Alberta
Update on HTN and ABPM Raj Padwal Division of General Internal Medicine University of Alberta Disclosures Funding: CIHR, AIHS, HSF, UHF Research Collaboration: Novo Nordisk, CVRx Consulting: Vivus, Medtronic
More informationThe Road to Renin System Optimization: Renin Inhibitor
The Road to Renin System Optimization: Renin Inhibitor A New Perspective on the Renin-Angiotensin System (RAS) Yong-Jin Kim, MD Seoul National University Hospital Human and Economic Costs of Hypertension
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationKDIGO conference on high CV risk associated with CKD. The role of BP in CKD stage 1-4
KDIGO conference on high CV risk associated with CKD The role of BP in CKD stage 1-4 Johannes Mann, MD & Catherine Clase, MB BChir Friedrich Alexander University, Erlangen-Nuremberg Munich General Hospitals,
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationInterventions to reduce progression of CKD what is the evidence? John Feehally
Interventions to reduce progression of CKD what is the evidence? John Feehally Interventions to reduce progression of CKD what is the evidence? CHALLENGES Understanding what we know. NOT.what we think
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationMANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE
MANAGEMENT CALL TO DISCUSS LONGER-TERM IMPROVEMENTS IN KIDNEY FUNCTION WITH BARDOXOLONE Introduction Substantial body of prior CKD clinical data characterizes Bard s unique profile Bard has demonstrated
More informationCHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW
CHRONIC KIDNEY DISEASE UPDATE: WHAT THE GENERALIST NEEDS TO KNOW MICHAEL G. SHLIPAK, MD, MPH CHIEF-GENERAL INTERNAL MEDICINE, SAN FRANCISCO VA MEDICAL CENTER PROFESSOR OF MEDICINE, EPIDEMIOLOGY AND BIOSTATISTICS,
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More information